we conclude that ( 1 ) the efrn can noninvasively detect significant changes in cardiac function at low cumulative doses of doxorubicin or daunomycin and ( 2 ) the efrn may be useful in evaluating cardiac function in patients during doxorubicin or daunomycin therapy .
C0013089
doxorubicin
C0011015
daunomycin